A new cross-Canada study has found that breast and prostate cancer treatment can foster bone loss. In the online edition of the Journal of Clinical Oncology, the scientists explain how loss of bone mass might affect 46,000 people diagnosed with breast and prostate cancer each year* and place them at increased risk for osteoporosis and fractures.
"Our study also looked at possible medications that can reverse or halt bone loss," says Dr. Fred Saad, lead author and director of urologic oncology at the Université de Montréal's Faculty of Medicine and the Centre Hospitalier de l'Université de Montréal (CHUM), who completed the exhaustive study with colleagues from McMaster University, the Université Laval, the University of Toronto and the University of British Columbia.
"Bone is a dynamic tissue which undergoes a cyclic process of breaking down and rebuilding," adds Dr. Saad. "Medications called bisphosphonates help with the rebuilding process and have been successfully used to combat osteoporosis, which is good news for cancer patients."
Evaluating the studies
Dr. Saad and colleagues evaluated data from more than 3,500 breast and prostate cancer studies. They concluded that breast cancer patients treated with aromatase inhibitors were more likely to have bone loss and fractures compared to patients who didn't receive the therapy. Similarly, men who received androgen deprivation therapy to treat their prostate cancer had an increased risk of bone disorders. Although the numbers vary from one study to the next (from five to 45 percent), an elevated risk is consistently observed.
"Awareness of the incidence of cancer-associated bone loss raises issues for clinicians who should identify those patients who are most at risk for fractures and prescribe treatment strategies," says Dr. Saad. "This information is not only a concern for the specialists, but also for the general practitioners who frequently encounter these patients."
Bisphosphonate treatment reduces bone loss
Dr. Saad's group also evaluated data that included bisphosphonate treatment for cancer patients receiving chemotherapy. Prostate cancer patients who received bisphosphonate treatment and androgen deprivation therapy did show an increase in bone loss. In the same vane, there was a protective effect on bone loss for breast cancer patients who were treated with bisphosphonates.
"It is clear that the use of bisphosphonates attenuates bone loss," concludes Dr. Saad. "However, the optimal dosing and long-term impact is unclear and needs to be determined. Other measures to combat the bone loss, such as exercise, vitamin D intake, avoidance of cigarettes, may also be beneficial
*(Re: Canadian Cancer Society)
About the study:
The article "Cancer Treatment–Induced Bone Loss in Breast and Prostate Cancer" (www.jco.ascopubs.org/cgi/reprint/JCO.2008.18.4184v1), published in the American Society of Clinical Oncology, was authored by Fred Saad from the Université de Montréal and the Centre hospitalier de l'Université de Montréal; Jonathan D. Adachi of McMaster University; Jacques P. Brown of the Université Laval; Leah A. Canning and Karen A. Gelmon of the University of British Columbia; Robert G. Josse and Kathleen I. Pritchard of the University of Toronto.
Sylvain-Jacques Desjardins | EurekAlert!
Win-win strategies for climate and food security
02.10.2017 | International Institute for Applied Systems Analysis (IIASA)
The personality factor: How to foster the sharing of research data
06.09.2017 | ZBW – Leibniz-Informationszentrum Wirtschaft
University of Maryland researchers contribute to historic detection of gravitational waves and light created by event
On August 17, 2017, at 12:41:04 UTC, scientists made the first direct observation of a merger between two neutron stars--the dense, collapsed cores that remain...
Seven new papers describe the first-ever detection of light from a gravitational wave source. The event, caused by two neutron stars colliding and merging together, was dubbed GW170817 because it sent ripples through space-time that reached Earth on 2017 August 17. Around the world, hundreds of excited astronomers mobilized quickly and were able to observe the event using numerous telescopes, providing a wealth of new data.
Previous detections of gravitational waves have all involved the merger of two black holes, a feat that won the 2017 Nobel Prize in Physics earlier this month....
Material defects in end products can quickly result in failures in many areas of industry, and have a massive impact on the safe use of their products. This is why, in the field of quality assurance, intelligent, nondestructive sensor systems play a key role. They allow testing components and parts in a rapid and cost-efficient manner without destroying the actual product or changing its surface. Experts from the Fraunhofer IZFP in Saarbrücken will be presenting two exhibits at the Blechexpo in Stuttgart from 7–10 November 2017 that allow fast, reliable, and automated characterization of materials and detection of defects (Hall 5, Booth 5306).
When quality testing uses time-consuming destructive test methods, it can result in enormous costs due to damaging or destroying the products. And given that...
Using a new cooling technique MPQ scientists succeed at observing collisions in a dense beam of cold and slow dipolar molecules.
How do chemical reactions proceed at extremely low temperatures? The answer requires the investigation of molecular samples that are cold, dense, and slow at...
Scientists from the Max Planck Institute of Quantum Optics, using high precision laser spectroscopy of atomic hydrogen, confirm the surprisingly small value of the proton radius determined from muonic hydrogen.
It was one of the breakthroughs of the year 2010: Laser spectroscopy of muonic hydrogen resulted in a value for the proton charge radius that was significantly...
17.10.2017 | Event News
10.10.2017 | Event News
10.10.2017 | Event News
20.10.2017 | Earth Sciences
20.10.2017 | Life Sciences
20.10.2017 | Life Sciences